IMR Press / FBE / Volume 10 / Issue 3 / DOI: 10.2741/E833

Frontiers in Bioscience-Elite (FBE) is published by IMR Press from Volume 13 Issue 2 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Review

p53 and P-glycoprotein influence chemoresistance in hepatocellular carcinoma

Show Less
1 Department of Pathology, The First Affliated Hospital of ZhengZhou University, ZhengZhou, 450000, China
2 Department of Oncology, The First Affliated Hospital of ZhengZhou University, ZhengZhou, 450000, China
3 Department of Interventional Therapy, The First Affliated Hospital of ZhengZhou University, ZhengZhou, 450000, China

*Author to whom correspondence should be addressed.

Front. Biosci. (Elite Ed) 2018, 10(3), 461–468; https://doi.org/10.2741/E833
Published: 1 June 2018
(This article belongs to the Special Issue Pathogenesis and diagnostic modalities in cancer)
Abstract

Chemoresistance is a critical obstacle to the treatment of hepatocellular carcinoma (HCC). The mechanisms underlying resistance to doxorubicin, cisplatin, and 5-fluorouracil involve p53 and P-glycoprotein (P-gp). p53 plays a role in cell growth; therefore, resistance mechanisms involve chemotherapy-induced apoptosis and p53 mutation and inactivation. P-gp is an energy-dependent drug efflux pump regulated by p53. Its role in drug resistance has provided new insights into the mechanisms underlying the involvement of p53 and P-gp in chemoresistance and may alter our traditional understanding of p53 and P-gp function. This review outlines the roles and principal mechanisms of p53 and P-gp mediated chemoresistance in HCC.

Keywords
p53
P-glycoprotein
Chemoresistance
Hepatocellular Carcinoma
Review
Share
Back to top